title: Good outcome in HIV-infected refugees after resettlement in New Zealand: population study.
abstract: BACKGROUND
  The aims of this study were to determine the clinical characteristics on arrival and the subsequent clinical outcome of HIV-infected UN quota refugees who settled in New Zealand during the last 11 years and to estimate their rate of HIV transmission.
  
  
  METHODS
  A population study was conducted. Data were provided by the Mangere Refugee Resettlement Centre, the infectious disease physicians caring for the subjects, the New Zealand AIDS Epidemiology Group and laboratories carrying out HIV viral load assays.
  
  
  RESULTS
  One hundred of 7732 (1.3%) UN quota refugees were HIV positive; mean age 30 years, 56% were men, median initial CD4 count was 320 (range 20-1358). HIV infection was most commonly acquired by heterosexual intercourse (74%). The median follow up was 5.0 years (range 1 month to 9.7 years). Five died and 15 subjects had 16 AIDS-defining illnesses, most commonly tuberculosis (n = 10). Sixty subjects commenced highly active antiretroviral therapy of whom 36/59 (61%) had an undetectable HIV viral load after 1 year of treatment. None of the six children born to HIV-infected women in New Zealand were infected. There were two known cases of horizontal transmission of HIV infection.
  
  
  CONCLUSIONS
  Although HIV-infected quota refugees often have to overcome severe social, cultural and financial handicaps, their clinical outcome is generally very good, with response rates to highly active antiretroviral therapy that are similar to other patient groups. Furthermore, they have not been a significant source of transmission of HIV infection after resettlement in New Zealand.
authors.affiliation: Department of Infectious Diseases, Auckland City Hospital, Aukland, New Zealand. mitzin@xtra.co.nz
authors.forename: S M
authors.initials: SM
authors.lastname: Nisbet
authors.forename: A M
authors.initials: AM
authors.lastname: Reeve
authors.forename: R B
authors.initials: RB
authors.lastname: Ellis-Pegler
authors.forename: A F
authors.initials: AF
authors.lastname: Woodhouse
authors.forename: R J
authors.initials: RJ
authors.lastname: Ingram
authors.forename: S A
authors.initials: SA
authors.lastname: Roberts
authors.forename: S M
authors.initials: SM
authors.lastname: McAllister
authors.forename: M G
authors.initials: MG
authors.lastname: Thomas
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D015897:Comorbidity; D004641:Emigration and Immigration; D005260:Female; D015658:HIV Infections / Q000453:epidemiology* / Q000628:therapy* / Q000635:transmission; D006801:Humans; D008297:Male; D008485:Medical Audit; D008875:Middle Aged; D009520:New Zealand; D012036:Refugees; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents